Claims for Patent: 9,096,660

Summary for Patent: 9,096,660

Title:	SPARC binding antibodies and uses thereof
Abstract:	The invention provides SPARC binding antibodies that target disease sites, in particular, tumors and uses thereof to diagnose and treat diseases, in particular, cancerous tumors.
Inventor(s):	Trieu; Vuong (Agoura Hills, CA), Liu; Xiping (Temple City, CA), Desai; Neil (Los Angeles, CA)
Assignee:	Abraxis BioScience, LLC (Los Angeles, CA)
Application Number:	13/643,609
Patent Claims:	1. A composition comprising a SPARC binding antibody, wherein the SPARC binding antibody comprises Imm-2, Imm-3, or a combination thereof. 2. The composition of claim 1 wherein the SPARC binding antibody comprises Imm-2. 3. The composition of claim 1 wherein the SPARC binding antibody comprises Imm-3. 4. The composition of claim 1 wherein the SPARC binding antibody comprises both Imm-2 and Imm-3. 5. The composition of claim 1, further comprising an active agent, wherein the active agent is conjugated to the SPARC binding antibody. 6. The composition of claim 5, wherein the active agent comprises a therapeutic agent or a diagnostic agent. 7. The composition of claim 6, wherein the therapeutic agent or diagnostic agent is a therapeutic agent selected from the group consisting of tyrosine kinase inhibitors, kinase inhibitors, biologically active agents, biological molecules, radionuclides, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, anti-vascular endothelial growth factor compounds ("anti-VEGFs"), anti-epidermal growth factor receptor compounds "anti-EGFRs"), 5-fluorouracil and derivatives, radionuclides, polypeptide toxins, apoptosis inducers, therapy sensitizers, enzyme or active fragment thereof, and combinations thereof. 8. The composition of claim 6, wherein the therapeutic agent or diagnostic agent is a therapeutic agent comprising an antibody or antibody fragment. 9. The composition of claim 8, wherein said antibody or antibody fragment is a Fc fragment of IgG, or IgA, or IgD, or IgE, or IgM. 10. The composition of claim 8, wherein said antibody or antibody fragment mediates one or more of complement activation, cell mediated cytotoxicity or opsonization, or mast cell activation, or other immune response. 11. The composition of claim 6, wherein the therapeutic agent or diagnostic agent is a diagnostic agent selected from the group consisting of flurochromes, radioactive agents, MRI contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents. 12. The composition of claim 1, wherein the composition is contained in a liposome. 13. The composition of claim 1, wherein the composition is contained in an albumin nanoparticle. 14. The composition of claim 1, wherein the composition further comprises a suitable pharmaceutical carrier. 15. The composition of claim 1, wherein said composition is administered to a patient via i.v., topically, via injection, via inhalation, intranasally, rectally or orally.

Details for Patent 9,096,660

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-03-29
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2039-03-29
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2039-03-29